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time (35 years ago). Very few skeletal radiologists par-
ticipated in the meeting then, and cooperation between
orthopedic surgeons and pathologists or radiologists is
still insufﬁcient. I feel strongly that this situation is caus-
ing problems such as misdiagnosis.
I experienced culture shock concerning this matter
several years later when I went to Boston to study.
After I had completed a 3-year pathology residency, I
studied at the Surgical Pathology Department of Massa-
chusetts General Hospital (MGH) in Boston. On my
ﬁrst day in the Surgical Pathology Department, I was
asked about X-ray diagnosis of bone tumor, not patho-
logical diagnosis, although I went there as a pathologist.
Because pathologists did not examine X-rays at that
time in Japan, I was at a loss. I learned later that bone
pathologists taught X-ray diagnosis of bones to resi-
dents in orthopedic surgery as well as to radiology
residents at MGH at that time. I felt that accurate
X-ray diagnosis was impossible without understanding
histopathology.
Considering how much my perception and “shock”
have changed after 40 years, on the occasion of this
Annual Musculoskeletal Tumor Meeting, I cannot help
feeling that the situation is still unsatisfactory. Thus,
these problems have been incorporated into the key-
note theme, symposia, and panel discussions for the
meeting. “Returning to the starting point of Jaffe’s tri-
angle: cooperation between imaging and pathological
diagnoses and surgical therapy” was made the keynote
theme. The term “Jaffe’s triangle” appearing in that
theme is an expression at the beginning of Tumors and
Tumorous Conditions of the Bones and Joints, the bible
of bone tumor pathology and classiﬁcation, published
by Professor Henry L. Jaffe in 1958, and is a concept
whereby orthopedic surgeons, pathologists, and skeletal
radiologists should cooperate in the diagnosis and treat-
ment of bone tumors. In the Society for Musculoskel-
etal Tumors in the 1970s mentioned earlier, orthopedic
surgeons performed all X-ray diagnosis, pathological
Nearly 40 years have passed since the 1st Annual Mus-
culoskeletal Tumor Meeting of the Japanese Orthopae-
dic Association (called the Forum of the Society for
Musculoskeletal Tumors at that time) was held in 1968.
Although the surgical ﬁeld of musculoskeletal tumors
has markedly advanced since then, the cooperation of
orthopedic surgeons with pathologists and radiologists
and collaboration with other medical practitioners are
still insufﬁcient. On the convening of the 39th Annual
Musculoskeletal Tumor Meeting of the Japanese Or-
thopaedic Association on July 6 and 7 this year at the
Sapporo Convention Center, I would like to share my
thoughts on the Annual Musculoskeletal Tumor Meet-
ing and on the diagnosis and treatment of musculoskel-
etal tumors that we encounter in routine practice.
After graduating from Hokkaido University, I started
my career as a pathologist, which I pursued for 7 years.
The ﬁrst time I participated in the Annual Musculoskel-
etal Tumor Meeting (“Forum” at that time) was at the
4th meeting, convened in 1971 by Dr. Maeyama, Profes-
sor of Orthopedics, Tottori University. Everything was
stimulating for me, just 1 year after my graduation. I
cannot forget the heated discussions between partici-
pants (orthopedic surgeons and pathologists) on histo-
logical diagnosis in case-report sessions. One thing I felt
at that time and still feel today is the importance of
thorough discussion of conventional H&E-stained sam-
ples. Diagnosis based on H&E staining tends to be
disregarded because diagnosis by immunohistological
staining has advanced, but this is the wrong order of
priority. It is time to reconsider diagnosis beginning
with H&E staining. Secondly, cooperation between
orthopedic surgeons and pathologists or radiologists
remains insufﬁcient: lack of information provided by
orthopedists was an issue raised by pathologists at that
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diagnosis, and treatment. Although the relationship
among orthopedic surgeons, pathologists, and skeletal
radiologists has markedly advanced and improved,
there are various problems with the relationship, and it
is still inadequate. The keynote theme was decided in
the belief that this would be a good time to go back to
the starting point of Jaffe’s triangle and reconsider that
relationship. A symposium with the same title has also
been planned.
“Limitations of H&E staining and problems of immu-
nohistochemical staining for pathological diagnosis of
musculoskeletal tumors” has also been designated as a
symposium topic. I want to return to the starting point
of H&E staining and discuss pathological diagnosis,
which is likely to lead to a bias toward speciﬁc staining
such as immunohistological staining.
For the treatment of bone and soft-tissue tumors,
cooperation with medical practitioners in other ﬁelds
has become increasingly important, and the symposium
and panel discussion have been planned with this in
mind. In the symposium “Postoperative quality of life
(QOL) of patients with malignant musculoskeletal
tumors: release from disability,” I am planning to invite
patients who have undergone surgery for malignant
musculoskeletal tumors to participate, and to discuss
what orthopedic surgeons should think and do from the
patients’ perspective to improve postoperative QOL,
with prosthetists also taking part. Treatment should no
longer be performed in consideration only of therapy
for malignant musculoskeletal tumors, but, rather, in
consideration of postoperative QOL as well. For the
future treatment of malignant musculoskeletal tumors,
consideration of the patient’s QOL involving nurses,
physical therapists, and those in other medical ﬁelds,
such as prosthetists, is important, expanding Jaffe’s tri-
angle to a pentagon and hexagon. In addition, I want to
turn the spotlight on terminal and palliative care for
patients in whom surgery or chemotherapy unfortu-
nately cannot resolve the tumor.
For the future of orthopedic therapeutic strategy for
musculoskeletal tumors, it is time to reinvestigate surgi-
cal procedures (preservation or dissection/amputation
of the affected limb, and indications of minimally inva-
sive surgery) to promote active participation in sports
and other activities after remission, and to introduce
terminal medical care based on consideration of
patients’ QOL, not simply targeting 5- and 10-year
survival rates.